The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1300 participants.
Also called NCT04981327
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,300 participants
- Registry
-
NCT04981327
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT04981327. Randomized; single masking; primary purpose treatment. Start 2022-09-01 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
- Acronym
- API-CALF
- Condition
- Deep Vein Thrombosis
- Intervention (Drug)
- Apixaban 2.5 MG Oral Tablet [ELIQUIS]
- Lead sponsor
- University Hospital, Geneva
- Collaborator
- Sunnybrook Health Sciences Centre
Record details
- Record id
cardio:ct-nct04981327- Content hash
06723d8fb023b36753a682b09195e02cd248817179c76a6894815d65dfaa9d46